Mario Huber, general manager of PharmaMar Austria, a multinational and an innovative oncology-based Spanish company, discusses the growth of the company in Austria and the reasons behind the success of Yondelis®, the company’s flagship product. Furthermore, he provides an overview of the clinical trials the Austrian affiliate is undertaking and the importance of Austria as a bridge market so PharmarMar can gain a foothold in the eastern European markets of Hungary, Slovakia and the Czech Republic.
As the general manager of PharmaMar Austria, could you introduce our international readers to the company?
"During the first few years that followed Yondelis®’s approval in ovarian cancer, Austria was selling more, in terms of volume of units, than the UK."
